06:49 AM EDT, 04/04/2025 (MT Newswires) -- Astrazeneca's ( AZN ) Imfinzi in combination with chemotherapy has been approved in the European Union for the treatment of adults with operable non-small cell lung cancer.

The specific indication for the treatment of patients at high risk of recurrence and no epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, the company said Friday.

Under the treatment plan, patients are treated with the drug, also known as durvalumab, in combination with neoadjuvant chemotherapy before surgery and as an adjuvant monotherapy after surgery, the company said.

The European Commission approval follows a positive opinion issued by the Committee for Medicinal Products for Human Use as well as results from a clinical trial in which the drug resulted in a 32% reduction in recurrence, progression, or death vs patients treated with chemotherapy alone, the company said.